Crystal form F of ibrutinib and preparation method

Abstract

The invention discloses a crystal form F of ibrutinib. The crystal form F is characterized in that X-ray powder diffraction (X-RPD) which adopts Cu-Kalpha radiation and is represented with a 2theta angle has diffraction peaks in positions at angles of 3.7 degrees plus or minus 0.2 degrees, 6.7 degrees plus or minus 0.2 degrees, 13.2 degrees plus or minus 0.2 degrees, 16.1 degrees plus or minus 0.2 degrees, 19.1 degrees plus or minus 0.2 degrees, 20.0 degrees plus or minus 0.2 degrees, 23.8 degrees plus or minus 0.2 degrees and 24.6 degrees plus or minus 0.2 degrees. Related solvents in a preparation process of the crystal form F are cheap, the conditions are mild, the operation is simple, good controllability and reproducibility are realized, further, the prepared crystal form has great stability, the HPLC (high performance liquid chromatography) purity is higher than 99%, and the phenomenon of crystal transformation can be avoided; besides, the solubility is high, the dissolubility is good, and the bioavailability is high.

Description

technical field [0001] The invention relates to the field of medicinal chemistry, in particular, the invention relates to a crystal form of ibrutinib, and a preparation method and use of the crystal form. Background technique [0002] Ibrutinib (Ibrutinib) is a first-in-class oral Bruton's tyrosine kinase (BTK) inhibitor, jointly developed by American Pharmacyclics and Johnson & Johnson, the trade name is Imbruvica, and its chemical name is: 1- [(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]- 2-propen-1-one, the structural formula is as follows: [0003] [0004] Ibrutinib irreversibly inhibits BTK by selectively covalently binding to the cysteine ​​residue (Cys-481) in the active site of the target protein Btk, thereby effectively preventing tumors from migrating from B cells to adapting to tumor growth. Environmental lymphoid tissue. In November 2013, the US Food and Drug Administration (FDA) approved its listing for the treatmen...

AI Technical Summary

Problems solved by technology

The operation of this method is cumbersome, there are repeated heating and cooling in the operation, and the production process is not easy to control

[0006] Suzhou Jingyun CN104327085A discloses another crystal form A (hereinafter referred to as crystal form A'), and its reported preparation method has three kinds: Method 1, dissolving the crude product of ibrutinib in a mixed solution of isopropanol and n-heptane In the method, crystal form A' was obtained by stirring at a speed of 750 revolutions per minute at room temperature. It is very difficult to industrialize such high-speed stirring; method 2, dissolving the crude ibrutinib in a mixed solvent of isopropanol and n-heptane , and at a cooling rate of 0.1 °C / min from 50 °C to 5 °C to obtain crystal form A, such a precise cooling rate is difficult to control; method 3, dissolve the crude ibrutinib in acetone, and then slowly add n-heptyl alkane, and stirred at a speed of 1000 rpm for 1 day to obtain Form A. This method requires a higher speed than Method 1, and it is more difficult to achieve industrialization.

And it has been reported that when these methods are repeated, the reproducibility is poor, and the crystal form A disclosed in WO2013 / 184572 will be obtained if the control is not good.

In addition, the existing dosage forms have low water solubility and low oral absorption bioavailability

Images